Menu
/REGISTER
PPB
Fielding
Montecito
Powershare
Loading...
You are here:  Home  >  Health Care  -  Page 40
Latest

Amgen partnering with Japanese company to develop biosimilars

By   /  Thursday, July 14th, 2016  /  Health Care, Latest news  /  Comments Off on Amgen partnering with Japanese company to develop biosimilars

Thousand Oaks-based biotech giant Amgen said July 13 it will partner with a Japanese company to develop and commercialize biosimilars in Japan. Under the partnership, Amgen will develop and manufacture biosimilars while Daiichi Sankyo will obtain marketing approval, distribution and commercialization rights in Japan for the products. The deal also includes several late-stage development drugs. Read More →

Read More →
Latest

FDA panel recommends Amgen biosimilar drug for approval

By   /  Tuesday, July 12th, 2016  /  Health Care, Latest news, Technology  /  Comments Off on FDA panel recommends Amgen biosimilar drug for approval

A Food and Drug Administration panel recommended an Amgen biosimilar drug for approval July 12, just days after it said the biosimilar performed like a drug it mimicked. ABP 501, made by Thousand Oaks biotech giant Amgen, replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and Read More →

Read More →
Latest

FDA OKs wearable injector for Amgen’s Repatha cholesterol drug

By   /  Monday, July 11th, 2016  /  Health Care, Latest news  /  Comments Off on FDA OKs wearable injector for Amgen’s Repatha cholesterol drug

The U.S. Food and Drug Administration approved a new type of injector for Amgen’s cholesterol reducing drug Repatha on July 11. The FDA approved a wearable injector, called the “Pushtronex” system, that sticks to patients’ bodies and delivers a dose of the drug monthly under the skin. Patients can perform moderate physical activities like walking Read More →

Read More →
Latest

FDA finds Amgen biosimilar replicates effects of Humira

By   /  Friday, July 8th, 2016  /  Health Care, Latest news, Tri-County Public Companies  /  Comments Off on FDA finds Amgen biosimilar replicates effects of Humira

The Food and Drug Administration said a new Amgen biosimilar replicates the effects of a competitor’s blockbuster drug July 8. ABP 501 replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and colon inflammation. The drug, made by Chicago-based competitor AbbVie, typically costs $20,000 per year for Read More →

Read More →
Latest

Health care nonprofits merge to expand Ventura County service

By   /  Friday, July 8th, 2016  /  Health Care, Latest news, Nonprofits  /  Comments Off on Health care nonprofits merge to expand Ventura County service

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Santa Barbara home health care service lifeline for seniors

By   /  Friday, July 8th, 2016  /  Health Care, right  /  Comments Off on Santa Barbara home health care service lifeline for seniors

Dr. Michael Bordofsky co-founded DASH, which provides home health care visits for the elderly. (Alex Kacik)

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Stellar Biotechnologies offerings raise $6.75 million

By   /  Thursday, July 7th, 2016  /  Health Care, Latest news, Tri-County Public Companies  /  Comments Off on Stellar Biotechnologies offerings raise $6.75 million

Stellar Biotechnologies, a Port Hueneme-based company which makes medicines from the blood of animals found only off the coast of California, closed two private offerings July 6. Stellar closed one offering of 1.7 million common shares sold to institutional investors for $4 per share. In a separate concurrent offering, the company also sold 1.3 million Read More →

Read More →